Dr. Steve O’Day works with melanoma and has seen great breakthroughs in targeted therapies and their impact on the disease.
Dr. David S. Siegel discusses the importance of understanding the molecular biology of myeloma. Physicians can now look at and offer alternative treatments to patients that they identify will most likely do poorly with traditional treatment. He believes this area will develop quickly over the next 2 to 5 years.
Alexander Bastian mentions that looking at more defined populations and leveraging the power of targeted medicine is improving the standard of care.
As we learn more about a person’s genetic makeup, the more we are able to target medicines to his/her needs and benefit. With continued research, Dr. Stainthorpe explains, we will be able to identify markers that allow us to target medicines more precisely to get better performance and reduce waste.
Dr. Palmer describes how the direct relationship between treatment directed to change in the DNA actually affects the outcome of patients.
Gary Palmer, MD, discusses the importance of patients knowing the DNA drivers of their cancer to slow the growth of their cancer.
Dr Agarwala discusses the optimal approach to providing information on targeted therapies to the oncology community.